Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on developing life-saving medicines, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Mike Andriole, the company's CEO, will deliver a corporate presentation on September 9, 2024, at 7:00 a.m. ET.
The presentation will be made available as an audio webcast on the Investor Relations section of Chimerix's website at ir.chimerix.com. Interested parties can access the webcast, which will remain archived on the site for approximately 90 days. This event provides an opportunity for investors and analysts to gain insights into Chimerix's latest developments and future strategies.
Chimerix (NASDAQ: CMRX), un'azienda biofarmaceutica focalizzata nello sviluppo di farmaci salvavita, ha annunciato la sua partecipazione alla 26a Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. Mike Andriole, CEO dell'azienda, terrà una presentazione aziendale il 9 settembre 2024, alle 7:00 a.m. ET.
La presentazione sarà disponibile come un webcast audio nella sezione Relazioni con gli Investitori del sito web di Chimerix su ir.chimerix.com. Le parti interessate possono accedere al webcast, che rimarrà archiviato sul sito per circa 90 giorni. Questo evento offre l'opportunità agli investitori e agli analisti di ottenere informazioni sugli ultimi sviluppi e sulle strategie future di Chimerix.
Chimerix (NASDAQ: CMRX), una empresa biofarmacéutica centrada en el desarrollo de medicamentos que salvan vidas, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. Mike Andriole, CEO de la compañía, presentará una exposición corporativa el 9 de septiembre de 2024, a las 7:00 a.m. ET.
La presentación estará disponible como un webcast de audio en la sección de Relaciones con Inversores del sitio web de Chimerix en ir.chimerix.com. Las partes interesadas pueden acceder al webcast, que se mantendrá archivado en el sitio por aproximadamente 90 días. Este evento proporciona una oportunidad para que inversores y analistas conozcan los últimos desarrollos y estrategias futuras de Chimerix.
Chimerix (NASDAQ: CMRX), 생명을 구하는 약물을 개발하는 데 중점을 둔 생물 의약품 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참가한다고 발표했습니다. 회사의 CEO인 Mike Andriole가 2024년 9월 9일 오전 7:00 ET에 기업 발표를 진행할 예정입니다.
발표는 Chimerix 웹사이트의 투자자 관계 섹션에서 오디오 웹캐스트로 제공됩니다. 관심 있는 분들은 ir.chimerix.com에서 웹캐스트에 접속할 수 있으며, 이 웹캐스트는 약 90일 동안 아카이브로 남아 있을 것입니다. 이 행사에서는 투자자와 분석가들이 Chimerix의 최신 발전 사항과 향후 전략에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Chimerix (NASDAQ: CMRX), une entreprise biopharmaceutique axée sur le développement de médicaments salvateurs, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. Mike Andriole, le PDG de l'entreprise, fera une présentation d'entreprise le 9 septembre 2024, à 7h00 ET.
La présentation sera disponible sous forme de webcast audio dans la section Relations Investisseurs du site web de Chimerix à l'adresse ir.chimerix.com. Les parties intéressées peuvent accéder au webcast, qui restera archivé sur le site pendant environ 90 jours. Cet événement offre une occasion aux investisseurs et aux analystes d'obtenir des informations sur les derniers développements et les stratégies futures de Chimerix.
Chimerix (NASDAQ: CMRX), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung lebensrettender Medikamente konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Mike Andriole, der CEO des Unternehmens, wird am 9. September 2024 um 7:00 Uhr ET eine Unternehmenspräsentation halten.
Die Präsentation wird als Audio-Webcast im Bereich Investor Relations der Website von Chimerix unter ir.chimerix.com verfügbar sein. Interessierte Parteien können auf den Webcast zugreifen, der etwa 90 Tage lang auf der Seite archiviert bleibt. Diese Veranstaltung bietet Investoren und Analysten die Möglichkeit, Einblicke in die neuesten Entwicklungen und zukünftigen Strategien von Chimerix zu erhalten.
- None.
- None.
DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will present a corporate presentation at the H.C. Wainwright 26th Annual Global Investment Conference made available on Monday, September 9, 2024 at 7:00 a.m. ET.
An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
CONTACT:
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
FAQ
When is Chimerix (CMRX) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Chimerix (CMRX) at the investment conference?
How can investors access Chimerix's (CMRX) presentation at the H.C. Wainwright conference?
How long will Chimerix's (CMRX) presentation be available on their website?
